Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Established Firms Have Most To Gain From Japanese Device Revisions

This article was originally published in The Gray Sheet

Executive Summary

Members of the Japanese Ministry of Health, Labor and Welfare are meeting with notified bodies (NBs) in the UK to better understand how elements of the European regulatory system would apply in Japan

You may also be interested in...



Mission Harmonization: QS Certification Should Align With Business Goals

The comment period on the final draft international standard for medical device quality management (ISO 13485) is being extended by a month with the hope that it will facilitate European adoption of the standard

Mission Harmonization: QS Certification Should Align With Business Goals

The comment period on the final draft international standard for medical device quality management (ISO 13485) is being extended by a month with the hope that it will facilitate European adoption of the standard

Japan Reforms Failed To Sate U.S. Firms In 2002; EU Reuse Drive Ebbs, Wanes

AdvaMed will capitalize on new Exec. VP-Global Strategy & Analysis Marjory Searing's rapport with Japan Ministry of Health, Labor & Welfare officials to renew its assault on foreign reference pricing in 2003

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT016371

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel